Abstract 3863
Background
One third of early breast cancers (EBC) in women are diagnosed over 70 years (y) old. In this population, clinicians look not only at EBC characteristics but also antecedents and comorbidities to determine the best treatment.
Methods
ConSoRe is a new generation data analytics solution using natural language processing and perform advanced data mining. It was used for data extraction from electronic patient record of 2048 patients (pts) of more than 70 years, operated for EBC in Centre Leon Berard since 1997. Patient and tumor characteristics, treatment and survival were extracted.
Results
Mean age was 75.5 y (range 70-100 y). Main comorbidities described were coronary heart disease: 340 pts (16,6%) and diabetes: 321 pts (15,7%). Distribution of body mass index (BMI) was under 18.5: 56 pts (3,3%), 18.5-25: 677 pts (39,6%); 25-30: 620 (36,3%) and over 30: 356 (20,8%). Mean tumor size was 23,5 mm (range 6 to 150), SBR grading was distributed as well: grade 1: 317 (17%) ; grade 2: 1007 (55%) ; grade 3: 476 (26%) while estrogen receptor were positive (>10%) in 1553 pts (86%), progesteron receptor positive (>10%) in 1299 pts (71%) and HER2 positive in 101 pts (6,3%). Histological nodes staging was N0 in 1497 pts (72%); N1 in 414 pts (20%); N2 in 95 pts (5%); N3 in 52 pts (2%). 295 pts (14%) were treated by chemotherapy, 80 pts (3,9%) by trastuzumab, 1544 pts (75%) by radiotherapy and 1543 (75%) by hormonotherapy. Despite a limited mean follow-up of 5,1 y (range 0.3-20,7y), we observe 83 local relapse (4%), 144 metastatic relapse (7%) and 261 deaths (12.7%) with a mean overall survival (OS) of 4,6 y (10 days to 21,4 y). In the multivariate analysis, BMI under 19 and HER 2 positive were independent predictors of OS (HR: 0,85; p = 2.49e-09). Using Multiple Correspondence Analysis, percentage of explained variances is very low with less than 10%. These results show the limit of classical approach by descriptive data analysis, that is why, we propose new method by machine learning and operational research to determine the best adjuvant treatment.
Conclusions
This elderly population has a poor prognosis for which taking BMI into account is important when defining the therapeutic strategy. Classical approaches by data analysis reach their limits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Heudel Pierre.
Funding
Has not received any funding.
Disclosure
P. Heudel: Research grant / Funding (institution): AstraZeneca; Honoraria (institution): novartis; Honoraria (self): Pfizer. O. Tredan: Honoraria (self): Roche; Honoraria (self): Pfizer; Honoraria (self): novartis; Honoraria (self): AstraZeneca; Honoraria (self): lilly; Honoraria (self): BMS; Honoraria (self): MSD. All other authors have declared no conflicts of interest.
Resources from the same session
2963 - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
Presenter: Ira Pekker
Session: Poster Display session 3
Resources:
Abstract
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract